XML 71 R55.htm IDEA: XBRL DOCUMENT

Contingent consideration (Tables)

12 Months Ended

Jun. 30, 2023

Statement [line items]

Summary of liabilities - contingent consideration


		2023 A$’000				2022 restated A$’000

Current Liabilities

Contingent consideration – Paxalisib			750				—
Contingent consideration – EVT801			—				759

			750				759


Non-current Liabilities
Contingent consideration - paxalisib			654				1,168
Contingent consideration – EVT801			5,467				7,041

			6,121				8,209

			6,871				8,968

Summary of reconciliation of contingent consideration


		Consolidated
						2022
		2023				restated
		$				$

Contingent consideration at start of period (current and non-current)			8,968				11,094
Payment of EVT801 milestone			—				(2,364	)
Interest on unwinding of discount			594				567
Effect of exchange rates on contingent consideration			697				(329	)
Gain on remeasurement of contingent consideration			(3,388	)			—

			6,871				8,968